Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 251

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 251
---
 by the Nasdaq,
the SEC or other regulatory authorities. Moreover, responding to such investigations are likely to consume a significant amount of our
management resources and cause us to incur significant legal and accounting expenses. Failure to remedy any material weakness in internal
control over financial reporting, or to maintain effective control systems, could also restrict our future access to the capital markets.
This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

93

As a public reporting company, we are subject
to filing deadlines for reports that we file pursuant to the Exchange Act, and our failure to timely file such reports may have material
adverse consequences on our business. 

Following the consummation
of the Business Combination, we failed to timely file our Form 8-K with Form 10 information prior to the “staleness” date
(as determined in accordance with the applicable rules and regulations of the SEC) applicable to the financial statements that were required
by the applicable accounting requirements and other rules and regulations of the SEC to be included in such filing (including pro forma
financial information); thus, we have not remained current in our reporting requirements with the SEC since we became an SEC reporting
company on February 14, 2024. Although we have since regained status as a current filer by filing a Form 8-K/A with current financial
statements on April 1, 2024, we will not be eligible to use a registration statement on Form S-3 that would allow us to continuously incorporate
by reference our SEC reports into the registration statement, or to use “shelf” registration statements to conduct offerings,
until approximately one year from the date we regained (and maintain) status as a current filer. Until such time, if we determine to pursue
an offering, we would be required to conduct the offering on an exempt basis, such as in accordance with Rule 144A, or file a registration
statement on Form S-1. Using a Form S-1 registration statement for a public offering would likely take significantly longer than using
a registration statement on Form S-3 and increase our transaction costs, and could, to the extent we are not able to conduct offerings
using alternative methods, adversely impact our liquidity, ability to raise capital or complete acquisitions in a timely manner. The use
of Form S-1 would also prevent us from conducting offerings on a “shelf basis,” limiting our flexibility as to the terms,
timing or manner of any such offering